Silvercrest Asset Management Group LLC Has $8.01 Million Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

Silvercrest Asset Management Group LLC cut its stake in shares of Twist Bioscience Co. (NASDAQ:TWST) by 0.9% in the 4th quarter, Holdings Channel reports. The institutional investor owned 172,343 shares of the company’s stock after selling 1,627 shares during the quarter. Silvercrest Asset Management Group LLC’s holdings in Twist Bioscience were worth $8,009,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of TWST. Van ECK Associates Corp raised its position in Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after purchasing an additional 267 shares during the last quarter. Banque Transatlantique SA acquired a new position in Twist Bioscience in the 4th quarter valued at approximately $43,000. US Bancorp DE raised its stake in shares of Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after acquiring an additional 601 shares during the last quarter. KBC Group NV lifted its holdings in shares of Twist Bioscience by 71.4% during the fourth quarter. KBC Group NV now owns 2,942 shares of the company’s stock worth $137,000 after purchasing an additional 1,226 shares during the period. Finally, Blue Trust Inc. grew its stake in shares of Twist Bioscience by 19.9% in the fourth quarter. Blue Trust Inc. now owns 4,567 shares of the company’s stock worth $206,000 after purchasing an additional 757 shares during the last quarter.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $30.93 on Monday. The firm has a 50 day moving average of $37.82 and a 200-day moving average of $43.31. The company has a market cap of $1.85 billion, a price-to-earnings ratio of -9.15 and a beta of 2.54. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 52 week low of $28.46 and a 52 week high of $60.90.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. On average, equities analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. decreased their price target on Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating for the company in a research note on Tuesday, May 6th. Robert W. Baird decreased their target price on shares of Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating for the company in a research report on Tuesday, May 6th. Guggenheim restated a “buy” rating and set a $50.00 price target on shares of Twist Bioscience in a report on Tuesday, May 6th. Barclays reduced their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a research note on Thursday, April 10th. Finally, Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Twist Bioscience currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.40.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 918 shares of the business’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $37,555.38. Following the completion of the sale, the senior vice president now owns 130,912 shares in the company, valued at approximately $5,355,609.92. The trade was a 0.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Emily M. Leproust sold 1,726 shares of the company’s stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $41.68, for a total transaction of $71,939.68. Following the transaction, the chief executive officer now owns 660,966 shares in the company, valued at approximately $27,549,062.88. The trade was a 0.26% decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,991 shares of company stock valued at $742,654 in the last three months. Corporate insiders own 3.01% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.